快要 飞的 《药股》 讨论区

葉芬

希望CVM會是下一只的DNDN。。





P/s: 猜猜看今晚的CVM股價是上 / 下？
        前2天是一天漲20仙。

[ 本帖最后由 葉芬 于 10-11-2009 04:15 PM 编辑 ]

葉芬

Future ... 紅字！

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,155.00  3:06am ET        Down 37.00 (0.36%)

m.i.k.e

原帖由 葉芬 于 10-11-2009 04:18 PM 发表
Future ... 紅字！

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,155.00  3:06am ET        Down 37.00 (0.36%)

哇 ! 五点了.....
今天准时收工.

晚上再聊.

葉芬

原帖由 m.i.k.e 于 10-11-2009 05:07 PM 发表
哇 ! 五点了.....
今天准时收工.

晚上再聊.

好。 晚上見。

葉芬

今晚VG走勢不錯，
見她紅了多天，今天才青回。

葉芬

昨晚 閉市 1.34，After Hours 1.27 - 今晚要是有1.2多會加碼5粒。


http://seekingalpha.com/article/ ... to-long-term-growth

Cel-Sci: Good News Could Lead to Long-Term Growth
November 10, 2009

As shares of Cel-Sci Corp. (CVM) have traded to the upside of late, the company is set to gain more exposure when it presents at the "7th Annual Vaccines: All Things Considered Conference" in Washington, DC on Tuesday afternoon.

While I don't expect the Cel-Sci stock to lose any of the recent trading volatility - mostly due to what I consider to be obvious manipulation and a fair number of short shares that need to be covered (as of October) - I do believe that recent developments, including the Cel Sci-Johns Hopkins LEAPS H1N1 study, have re-enforced the long term positive outlook of the company.

Tuesday's presentation will not likely bring any new developments to the table, but there is enough pending news with Cel-Sci right now to keep both long- and short-term investors interested. Aside from the LEAPS H1N1 trial, news regarding the validation of the Baltimore area manufacturing facility continues to be expected in the fourth quarter.

Once that news is released, I then expect a news release announcing the commencement of the long awaited Multikine Phase III trial to follow shortly thereafter.

With volatility of the CVM stock likely to continue, I maintain my position of buying the dips. I think that we have a winner with CVM - especially for those with a long term outlook.

Disclosure: VFC is long CVM.

m.i.k.e

http://money.cnn.com/news/newsfe ... SPR_____SF08379.htm

Poniard Pharmaceuticals to Present Updated Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and Final Phase 1 Cardiac Safety Trial Results

-- Data To Be Presented at AACR-NCI -EORTC's 'Molecular Targets and Cancer Therapeutics' International Conference --
November 10, 2009: 08:00 AM ET


SOUTH SAN FRANCISCO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial. The data from both trials will be presented at a poster session during the AACR-NCI -EORTC’s "Molecular Targets and Cancer Therapeutics" International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company’s lead product candidate.

Poster presentation details are as follows:

    Randomized Phase 2 study of Picoplatin in Combination with 5-fluorouracil
     and Leucovorin (FOLPI) as a Neuropathy-Sparing Alternative to mFOLFOX-6
     as First-line Therapy for Colorectal Cancer (CRC)
    Abstract #B49
    R.L. De Jager, S. V. Cheporov, O. A. Gladkov, M. Y. Biakhov, H. B. Breitz,
     R. H. Earhart, and the FOLPI Study Group
    Poster Session B: Clinical Trials 2
    Tuesday, November 17, 12:30-2:30 p.m. Eastern Time
    Halls C-D, Hynes Convention Center

    QTc Study of Picoplatin with Emphasis on Pharmacodynamics of Cardiac
     Repolarization
    Abstract #B212
    R. H. Earhart, L. Rosen, D. Mendelson, S. Plaxe, P. Gold, L. Yee,
     S. Mansoor, C. Verschraegen, A. Phillips, S. Houston, and R.L. De Jager
    Poster Session B: Pharmacokinetics and Pharmacodynamics 1
    Tuesday, November 17, 12:30-2:30 p.m. Eastern Time
    Halls C-D, Hynes Convention Center


About Picoplatin

Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. It is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors.

In addition to the Phase 1 cardiac safety assessment and the Phase 2 trial in patients with colorectal cancer, Poniard is evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR trial in patients with small cell lung cancer, and in a Phase 2 clinical trial in patients with castration-resistant prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Poniard has received both Orphan Drug designation and Fast Track designation for picoplatin for the second-line treatment of refractory or resistant SCLC from the FDA and orphan medicinal product designation for the treatment of SCLC by the European Commission.

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PARD 7.85
-0.60 (-7.10%)
After Hours: 7.85 0.00 (0.00%)
Nov 10, 6:03PM EST  

昨晚股价跌, 是不是研究成绩不好? Insider 应该已经知道成绩了吧?!!

可是,要是成绩不好,随便来个 press release 不就好了, 为什么还要这么大阵战的在 international conference 里公布?

[ 本帖最后由 m.i.k.e 于 11-11-2009 11:38 AM 编辑 ]

葉芬

Date        Open        High        Low        Last        Change        Volume        % Change
11/10/09        1.41        1.41        1.31        1.34        -0.07        4482000        -4.96%

Composite Indicator        
   Trend Spotter TM                Sell

Short Term Indicators        
   7 Day Average Directional Indicator        Buy        
   10 - 8 Day Moving Average Hilo Channel        Buy        
   20 Day Moving Average vs Price        Buy        
   20 - 50 Day MACD Oscillator                Sell
   20 Day Bollinger Bands                Hold        

Short Term Indicators Average:          40% - Buy
20-Day Average Volume - 8692430

Medium Term Indicators        
   40 Day Commodity Channel Index                Hold        
   50 Day Moving Average vs Price        Buy        
   20 - 100 Day MACD Oscillator        Buy        
   50 Day Parabolic Time/Price        Buy        

Medium Term Indicators Average:          75% - Buy
50-Day Average Volume - 13393958

Long Term Indicators        
   60 Day Commodity Channel Index                Hold        
   100 Day Moving Average vs Price        Buy        
   50 - 100 Day MACD Oscillator        Buy        

Long Term Indicators Average:          67% - Buy
100-Day Average Volume - 8393191

Overall Average:          48% - Buy

Price         Support         Pivot Point         Resistance
1.34         1.25         1.35         1.45


*我每次看這Technical Opinion & Details Quote 時，是很注意Support & Resistance，那樣才知道股價會上到那及調整到那裏。。。 不知道其他網友有沒有注意？


Support 1.25 Hold 不住的話，下一價錢就是1.17 了。。。

[ 本帖最后由 葉芬 于 11-11-2009 12:42 PM 编辑 ]

葉芬

YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,253.00  2:26am ET        Up 36.00 (0.35%)





題外話：

Wow 這次版主們的辦事能力很強。值得贊許。
按了報告不到10分鐘，就消滅了。

[ 本帖最后由 葉芬 于 11-11-2009 03:49 PM 编辑 ]

葉芬

Wow


YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,269.00  3:13am ET        Up 52.00 (0.51%)

miku

看海很爽的。。赚了钱就要开心。明天回来。

大家要注意abk。明天如果大市跌，他会跌更加厉害。 他自己说可能会倒。不过还没倒。。 适合投机。

韦一笑

原帖由 miku 于 11-11-2009 11:15 PM 发表
看海很爽的。。赚了钱就要开心。明天回来。

大家要注意abk。明天如果大市跌，他会跌更加厉害。 他自己说可能会倒。不过还没倒。。 适合投机。

miku要到哪里去看海？那里的海好看？

葉芬

麥麥： HLCS 大跌。。 你之前的有放了嗎？


P/s: 我的在2.71時放了。。

[ 本帖最后由 葉芬 于 12-11-2009 04:43 AM 编辑 ]

m.i.k.e

原帖由 葉芬 于 12-11-2009 04:42 AM 发表
麥麥： HLCS 大跌。。 你之前的有放了嗎？


P/s: 我的在2.71時放了。。

惨了.....我手头上还有整 1000 股. 怎么办?

FRE 1.18  
-0.02 (-1.67%)
After Hours: 1.17 -0.01 (-0.85%)
Nov 11, 5:56PM EST


我的身家大缩水. 看来要闭门检讨三个月才行了......

葉芬

CVM  閉市1.32
After Hours 1.31

在閉市時我看著價錢從1.27沖上1.32， 1.38， 1.35， 不知為何他們拿1.32 做準。
昨晚1.25 再投機5粒。看今晚情形如何。。
本來還想再排1.20多5粒，不過覺得還是不要太貪心。。
呵呵要是有排又排到了。。

葉芬

原帖由 m.i.k.e 于 12-11-2009 07:42 AM 发表


惨了.....我手头上还有整 1000 股. 怎么办?

FRE 1.18  
-0.02 (-1.67%)
After Hours: 1.17 -0.01 (-0.85%)
Nov 11, 5:56PM EST


我的身家大缩水. 看来要闭门检讨三个月才行了......

HLCS Technical Chart 說 很可能會下到 0.40
希望這消息不準。。

http://community.smallcapnetwork.com/Technical-Review-of-MGI-HOV-and-HLCS/s/article/view/p/mid/2/id/129/

I thought Helicos BioSciences Corp. (NASDAQ:HLCS)might have a shot at finding support at $1.60, as it did last week. Thepressure was too great though, pushing the stock under a key floor.

Thatlevel wasn't pulled out of thin air for Helicos BioSciences shares.It's the 61.8% Fibonacci retracement level for the entire July/Augustrally. Now that it's snapped with today's low of $1.41, HLCS is free tomove back to July's lows around $0.40.

You can't quite make itout yet, but the downtrend from Helicos BioSciences is gatheringvolume. The last two days have been heavier-than-average distributiondays. That doesn't help.








XXXXXXXXXXXXXXXXXXXX


說起身家，師父的 HGSI 1粒就能頂普通的10粒了。。



[ 本帖最后由 葉芬 于 12-11-2009 10:29 AM 编辑 ]

葉芬

分享：VFC寫的東西真的是不錯。這是特別供新人參考。



Readers Respond: CVM and New Investor Notes

http://vfcsstockhouse.blogspot.c ... d-new-investor.html


XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX


VFC's Take on a Couple of Investor Questions: When to Take Gains and Where to Start With DD?

http://vfcsstockhouse.blogspot.c ... le-of-investor.html


XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX


Some Investing Tips for New Investors
New Investor Questions Answered

http://vfcsstockhouse.blogspot.c ... -new-investors.html


XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX


VFC's Thoughts for the Day - Exercise Patience

http://vfcsstockhouse.blogspot.c ... rcise-patience.html

葉芬

應該是算好消息吧：

CEL-SCI
Join the Team

POSITION: Quality Assurance Auditor/Validation Specialist (2 positions available)

DEPARTMENT: Quality Assurance

EDUCATION: BA/BS in Life Sciences or Engineering Sciences

EXPERIENCE: 5 + years of QA experience in the FDA, CGMP regulated Pharmaceutical or Biopharmaceutical business.

http://cel-sci.com/careers_qa_vs.html

葉芬

今晚Future 暫時是不妙。


YMZ09.CBT        Mini Dow Jones Indus.-$5 Dec 09        10,228.00  1:55am ET        Down 31.00 (0.30%)

[table=540][/table]

[ 本帖最后由 葉芬 于 12-11-2009 03:10 PM 编辑 ]

m.i.k.e

原帖由 葉芬 于 12-11-2009 09:57 AM 发表



HLCS Technical Chart 說 很可能會下到 0.40
希望這消息不準。。

http://community.smallcapnetwork.com/Technical-Review-of-MGI-HOV-and-HLCS/s/article/view/p/mid/2/id/129/

I thought Hel ...


說起身家，師父的 HGSI 1粒就能頂普通的10粒了。。

就是拿来顶那几粒亏大钱的 HEB  和 CTIC........